Use of docetaxel after paclitaxel hypersensitivity reaction in epithelial ovarian and endometrial cancer

Clinical Ovarian Cancer

Volumn 2, Issue 1, 2009, Pages 44-47

  Isonishi, Seiji ^a   Suzuki, Michiko ^a   Hirama, Masanori ^a   Matsumoto, Ryuma ^a   Ochiai, Kazuhiko ^a   Tanaka, Tadao ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Body mass index; Drug substitution; Dyspnea; Taxanes

Indexed keywords

CARBOPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; DOCETAXEL; PACLITAXEL; RANITIDINE; TAXANE DERIVATIVE;

ADJUVANT THERAPY; ADULT; ANAPHYLAXIS; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL FEATURE; DRUG EFFECT; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; EDEMA; ENDOMETRIUM CANCER; FACE ERYTHEMA; FEMALE; FLUSHING; HEART PALPITATION; HUMAN; HYPERSENSITIVITY REACTION; HYPOTENSION; LUNG PRESSURE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVARY CANCER; OXYGEN SATURATION; PARESTHESIA; PRIMARY TUMOR; SIDE EFFECT; TACHYCARDIA; THERAPY EFFECT; TREATMENT RESPONSE; UNIVERSITY HOSPITAL; URTICARIA; VOMITING;

EID: 77953421711     PISSN: 19414390     EISSN: 19414404     Source Type: Journal    
DOI: 10.3816/COC.2009.n.006     Document Type: Article

References (22)

1. Moon C, Verschraegen CF, Bevers M, et al. Use of docetaxel (Taxotere) in patients with paclitaxel (Taxol) hypersensitivity. Anticancer Drugs 2000; 11: 565-8.
2. Bernstein BJ. Docetaxel as an alternative to paclitaxel after acute hypersensitivity reactions. Ann Pharmacother 2000; 34: 1332-5.
3. Vasey PA, Atkinson R, Coleman R, et al. Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer. Br J Cancer 2001; 84: 170-8.
4. Denman JP, Gilbar PJ, Abdi EA. Hypersensitivity reaction (HSR) to docetaxel after a previous HSR to paclitaxel. J Clin Oncol 2002; 20: 2760-1.
5. Dizon DS, Schwartz J, Rojan A, et al. Cross-sensitivity between paclitaxel and docetaxel in a women's cancers program. Gynecol Oncol 2006; 100: 149-51.
6. Cantu MG, Buda A, Parma G, et al. Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. J Clin Oncol 2002; 20: 1232-7.
7. Markman M, Kennedy A, Webster K, et al. Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland Clinic Cancer Center. J Clin Oncol 2000; 18: 102-5.
8. Sendo T, Sakai N, Itoh Y, et al. Incidence and risk factors for paclitaxel hypersensitivity during ovarian cancer chemotherapy. Cancer Chemother Pharmacol 2005; 56: 91-6.
9. Castells MC, Tennant NM, Sloane DE, et al. Hypersensitivity reactions to chemotherapy: Outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol 2008; 122: 574-80.
10. Lokich J, Anderson N. Paclitaxel hypersensitivity reactions: A role for docetaxel substitution. Ann Oncol 1998; 9: 573-4.
11. Olson JK, Sood AK, Sorosky JI, et al. Taxol hypersensitivity: rapid retreatment is safe and cost effective. Gynecol Oncol 1998; 68: 25-8.
12. Cormio G, Di Vagno G, Melilli GA, et al. Hypersensitivity reactions in ovarian cancer patients receiving paclitaxel. J Chemother 1999; 11: 407-9.
13. Francis PA, Rigas JR, Kris MG, et al. Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer. J Clin Oncol 1994; 12: 1232-7.
14. Pazdur R, Lassere Y, Soh LT, et al. Phase II trial of docetaxel (Taxotere) in metastatic colorectal carcinoma. Ann Oncol 1994; 5: 468-70. (Pubitemid 24159656)
15. Gardner ER, Dahut WL, Scripture CD, et al. Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel. Clin Cancer Res 2008; 14: 4200-5.
16. Micha JP, Goldstein BH, Birk CL, et al. Abraxane in the treatment of ovarian cancer: the absence of hypersensitivity reactions. Gynecol Oncol 2006; 100: 437-8.
17. Green MR, Manikhas GM, Orlov S, et al. Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced nonsmall- cell lung cancer. Ann Oncol 2006; 17: 1263-8.
18. Kim TY, Kim DW, Chung JY, et al. Phase I and pharmacokinetic study of Genexol- PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res 2004; 10: 3708-16.
19. Isonishi S, Yasuda M, Takahashi F, et al. Randomized phase III trial of conventional paclitaxel and carboplatin (c-TC) versus dose dense weekly paclitaxel and carboplatin (dd-TC) in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: Japanese Gynecologic Oncology Group trial (JGOG3016). J Clin Oncol 2008; 26(15 suppl): 294S (Abstract 5500).
20. de Jongh FE, de Wit R, Verweij J. e al. Dose-dense cisplatin/paclitaxel: a well-tolerated and highly effective chemotherapeutic regimen in patients with advanced ovarian cancer. Eur J Cancer 2002; 38: 2005-13.
21. Seidman AD, Berry D, Cirrincione C, et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B Protocol 9840. J Clin Oncol 2008; 26: 1642-9.
22. Sparano JA, Wang M, Martino S, et al. Davidson. Weekly Paclitaxel in the Adjuvant Treatment of Breast Cancer. N Engl J Med 2008; 358: 1663-71.